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Abstract
The growth hormone (GH) and insulin-like growth factor (IGF) system plays an important role in the regulation of cell proliferation, dif-
ferentiation, apoptosis, and angiogenesis. In terms of cell cycle regulation, the GH-IGF system induces signalling pathways for cell growth 
that compete with other signalling systems that result in cell death; thus the final effect of these opposed forces is critical for normal and 
abnormal cell growth. The association of the GH-IGF system with carcinogenesis has long been hypothesised, mainly based on in vitro 
studies and the use of a variety of animal models of human cancer, and also on epidemiological and clinical evidence in humans. While 
ample experimental evidence supports a role of the GH-IGF system in tumour promotion and progression, with several of its components 
being currently tested as central targets for cancer therapy, the strength of evidence from patients with acromegaly, GH deficiency, or 
treated with GH is much weaker. In this review, we will attempt to consolidate this data. (Endokrynol Pol 2016; 67 (4): 414–426)
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Streszczenie
Oś hormon wzrostu (GH)–insulinopodobny czynnik wzrostu (IGF) odgrywa istotną rolę w regulacji proliferacji i różnicowania komórek, 
apoptozy i angiogenezy. Oś GH–IGF wpływa na regulację cyklu komórkowego przez pobudzenie szlaku wzrostu komórki w stosunku 
do szlaków sygnałowych prowadzących do śmierci komórki, a ostateczny efekt oddziaływania tych dwóch sił ma podstawowe znaczenie 
dla prawidłowego lub nieprawidłowego wzrostu komórki. Hipotezy na temat powiązań osi GH–IGF z karcynogenezą pojawiły się wiele 
lat temu, głównie w oparciu o wyniki badań in vitro oraz badań z wykorzystaniem różnych zwierzęcych modeli raka występującego 
u ludzi. Chociaż liczne dane doświadczalne potwierdzają rolę osi GH–IGF sprzyjającą rozwojowi i progresji nowotworów, a nad kil-
koma składowymi tej osi trwają obecnie badania oceniające ich przydatność jako główne cele terapii przeciwnowotworowej, to jednak 
siła dowodów uzyskanych u chorych z akromegalią, niedoborem GH lub osób leczonych GH jest znacznie słabsza. W niniejszej pracy 
przeglądowej spróbowano zebrać wszystkie te dane. (Endokrynol Pol 2016; 67 (4): 414–426)
Słowa kluczowe: hormon wzrostu; insulinopodobny hormon wzrostu; rak; karcynogeneza
Introduction
Mechanisms controlling cell proliferation are depend-
ent of a complex cascade of events that, when altered 
or disrupted, can lead to a substantial increase in the 
risk of carcinogenesis. The growth hormone (GH) and 
insulin-like growth factor (IGF) system, which consists 
of GH, GH receptor (GHR), two growth factors (IGF-I 
and IGF-II), two cell surface receptors (IGF-IR and 
IGF-IIR), six binding proteins (IGFBPs), and a group of 
proteases, play a central role in the regulation of body 
growth and metabolic processes [1–5].
Growth hormone and IGFs have the ability to 
promote cell proliferation, differentiation, and an-
giogenesis, and they also inhibit apoptosis, potentially 
favouring tumour development. In contrast, other play-
ers of the IGF system, such as IGFBP-3, proteases, and 
IGFRs, have been shown to modulate IGF actions by 
inhibiting cell proliferation, stimulating apoptosis, 
and helping to determine cell survival. In turn, both 
circulating IGFBP-3 and IGF-I levels are dependent 
on and induced by GH. Consequently, the GH-IGF 
system induces signalling pathways for cell growth 
that compete with other signalling systems resulting 
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in cell death. The final effect of these opposed forces in 
a tissue-specific environment is critical for normal and 
abnormal cell growth [1–5].
The association between the GH and IGF system 
and carcinogenesis has long been postulated based on 
experimental, epidemiological, and clinical data. In the 
1950s, the potential role of GH in carcinogenesis was 
demonstrated by suppression of metastases develop-
ment in hypophysectomised rats, resulting in attempts 
to treat advanced cancers in humans by surgical pi-
tuitary ablation [6, 7]. More recently, genome-wide as-
sociation studies (GWAS) have identified GH-induced 
signalling pathways as the third highest pathway as-
sociated with breast cancer susceptibility, opening new 
therapeutic perspectives [8]. The preponderance of data 
suggests a slight increased risk of some cancers due to 
higher activity of the GH-IGF system and a protective 
effect against developing cancer in states of GH and 
IGF-I deficiencies. This article reviews the different 
sources of experimental human and animal studies, as 
well as the existing epidemiological and clinical data, 
implicating the GH and IGF system with cancer risk. 
GH and IGF system
Pituitary GH secretion is pulsatile and mainly regulated 
by two hypothalamic peptides: GH-releasing hormone 
(GHRH) and somatostatin. GHRH induces GH gene 
transcription and hormone release, while somatosta-
tin suppresses both basal and GHRH-stimulated GH 
pulses. In addition, the stomach derived peptide ghrelin 
represents an additional stimulus for GH secretion, 
acting through the GH secretagogue (GHS) receptors 
expressed in somatotroph cells. After secretion, roughly 
40-45% of circulating GH binds to a high-affinity GH 
binding protein (GHBP), which represents the extracel-
lular domain of the GH receptor (GHR) [9]. GHRs are 
ubiquitously distributed and they are present as con-
stitutive dimers in the cell membranes. GHR activation 
by GH binding results in structural rearrangements of 
the GHR that ultimately results in activation of JAK-2 
and STAT-5, but can also trigger the mitogen-activated 
protein kinase (MAPK), Akt/phosphoinositide 3-kinase 
(PI3K), and other intracellular signalling pathways [10]. 
Growth hormone stimulates the production of IGF-I 
primarily by the liver, which is the major source of circu-
lating IGF-I, IGFBPs, and, plausibly, IGF-II [9, 11]. IGF-I 
is also produced in several other tissues in response 
to GH and exerts a negative feedback effect on GH 
secretion by stimulation of somatostatin release in the 
hypothalamus and inhibition of GH gene transcription 
in the pituitary. The IGFBPs comprise a superfamily of 
six proteins (IGFBP-1 to -6) that bind to IGFs with high 
affinity and specificity and a family of IGFBP-related 
proteins (IGFBP-rPs), which are structurally similar 
to the IGFBPs but bind IGFs with much lower affinity 
[5]. In plasma, most IGFs are associated with a high 
molecular weight complex (a ternary complex) consist-
ing of IGFBP-3 and the acid labile subunit (ALS). Less 
than 1% of total IGF-1 is free. Circulating IGF-I levels 
rise during juvenile life and then decline after puberty, 
while circulating IGF-II levels are highest in the foetal 
circulation [11]. When the ternary complex dissociates, 
the binary complexes of IGFBP-IGF are removed from 
the circulation and cross the endothelium to reach the 
target tissues. The cellular responses to the IGFs are 
mediated by the IGF receptors, members of the tyros-
ine kinase growth factor family, and by IGFBPs, which 
modulate the ligand-receptor interaction by binding 
with higher affinity to the IGFs than the cognate recep-
tors or by acting as a reservoir that can slowly release 
the ligands. IGFs and IGFBPs are also locally produced 
in many other tissues, where autocrine or paracrine 
mechanisms take place and where IGFs actions are also 
regulated by IGFBP proteases [2-5].
The IGF system comprises two main receptors (IGF-IR 
and IGF-IIR). IGF-IR is a hetero-tetramer formed by 
two identical a-subunits and two identical b-subunits, 
exhibiting high homology with the insulin receptor (IR). 
In fact, IGF-I, IGF-II, and insulin can cross-bind to each 
other’s receptor with much lower affinity than that ob-
served for the authentic ligand. The homology between 
IGF-IR and IR permit the formation of hybrid receptors, 
composed of one a-subunit and one b-subunit of each 
receptor, the amounts of which vary from tissue to tis-
sue. These hybrid receptors have higher binding affin-
ity for IGF-I than for insulin, and despite the fact that 
their biologic significance remains mostly unknown, 
it is thought that they function mainly as an IGF-IR, 
i.e. by activating downstream targets that lead to cellular 
proliferation [4, 5, 11].
The mitogenic activity of the IGF-IR is mediated 
through the Ras and AKT pathways and results in the 
upregulation of Cyclin D and its binding partner CDK4. 
Under non-dividing cell conditions, retinoblastoma 
protein (Rb) is bound with the E2F transcription fac-
tor. When CDK4 is activated and is bound with Cyclin 
D, the Cyclin D/CDK4 complex phosphorylates Rb 
and E2F is released. The released E2F is then free to 
act as a transcription factor, activating expression of 
downstream target genes like Cyclin E [12]. The AKT 
pathway plays a critical role in apoptosis by inhibiting 
pro-apoptotic proteins like BAD and FKHR and acti-
vating anti-apoptotic factors such as NF-kappa B and 
MDM2. Moreover, IGF-IR activation downregulates cell 
cycle suppressors such as p27kip1, p57kip2, and PTEN. 
IGF receptors inducible pathways might share signal-
ling crosstalk with other receptor/signalling systems, 
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resulting in multiple interconnected pathways with im-
portant physiologic and therapeutic implications [4, 5].
IGF-IIR is a type I transmembrane glycoprotein 
with a large extracellular domain consisting of three 
ligand-binding regions: one for IGF-II and two for 
proteins containing mannose-6-phosphate (M6P) 
and the dormant form of transforming growth factor 
beta (TGF-b). For this reason, IGF-IIR is also called the 
IGF-II/M6P receptor. IGF-IIR exhibits structural and 
biochemical differences with IGF-IR and IR. Also, the 
extracellular domain of the IGF-IIR dissociates from the 
cell membrane as a soluble fragment, circulating in the 
blood with the ability to bind to IGF-II and facilitate its 
degradation. IGF-IIR does not transduce an intracel-
lular signal, but rather acts to reduce the bioactivity of 
IGF-II by sequestering it away from the IGF-IR. Thus, 
in addition to IGFBPs, IGF-IIR provides extra control 
for the circulating levels of IGFs, functioning as a “sink” 
that controls the local bioavailability of IGF ligands for 
binding to the IGF-IR [4, 5, 11]. Figure 1 illustrates the 
relationship among the main components of the GH-
IGF system.
Experimental evidence
In vitro studies
GH, IGF-I, and their receptors have been identified in 
a variety of solid and haematological malignancies, in-
cluding breast, prostate, brain, thyroid, pancreas, ovary, 
colorectal, and renal cancer cells, and their increased 
expression has been associated with poorer therapeutic 
response to radio- and chemotherapy [3, 4]. GH and IGFs 
might stimulate tumour growth by either direct effects 
on cell proliferation, differentiation, and survival or by 
synergy with other growth factors. In addition, IGFs 
have been shown to exhibit angiogenic properties and 
to be able to promote metastases. Neutralisation of IGF 
actions and disruption of the IGF-R-induced pathways 
have been tested as targets for novel cancer therapies [5].
The possibility of GH acting through an autocrine/
paracrine manner has been investigated in human 
endometrial carcinoma cell lines RL95-2 and AN3. 
These cell lines were stably transfected with a plasmid 
designed to express human GH (hGH) [13]. Both AN3-
vector (control cells) and AN3-hGH cell lines expressed 
equivalent levels of the GHR, while AN3-hGH secreted 
detectable levels of hGH into the culture medium. 
Compared to control AN3-vector-containing cells, the 
AN3-hGH cells grow significantly faster over a 14-day 
period and demonstrated enhanced anchorage-
independent cell growth. Similar results were found 
with the RL95-2 cell line. In addition, antagonism of 
GH-induced signalling by B2036 (a GHR antagonist) 
resulted in reduction of cell oncogenic properties. These 
studies demonstrate a functional role for autocrine GH 
in the development and progression of endometrial 
carcinoma and indicate potential therapeutic relevance 
of GHR antagonism. Similar findings have recently been 
reported on oestrogen receptor (ER)-positive mammary 
carcinoma cells [14]. On the other hand, another study 
that investigated the role of the GH/IGF-I axis on glioma 
cell lines demonstrated that, even in the presence of 
a low GH/IGF-I environment, the growth of glioma tu-
mour cells could not be inhibited in vivo, suggesting the 
involvement of other signals for cell proliferation [15]. In 
agreement, intracellular signalling ‘crosstalk’ pathways 
have been identified between IGF-IR and the erbB fam-
ily of receptors, which include erbB1 (EGFR) and erbB2 
(HER2/neu), in ovarian and breast cancer, and IGF-IR 
and ER in breast cancer [4]. These ‘crosstalking’ pathways 
might have important therapeutic implications, possibly 
contributing to drug resistance. Different strategies have 
been attempted to overcome this problem. For instance, 
dual therapy directed to different targets with IMC-A12 
(anti-IGF-IR antibody) and cetuximab (anti-EGFR anti-
body) has been tested in head and neck cancer and with 
IMC-A12 and lapatinib (tyrosine-kinase inhibitor against 
HER2) in breast cancer [4].
IGFBPs have been shown to be synthesised in some 
malignant tissues, such as lung, breast, and ovarian 
cancers. They might impact carcinogenesis by several 
mechanisms, including regulation of bioavailability of 
IGFs in circulation and interactions with extracellular 
proteases that degrade IGFBPs and release ligand for 
subsequent receptor activation. Some proteolytic frag-
ments, particularly of IGFBP-5, -4, and -3, may also 
exhibit ligand-independent biological activities [2–4]. 
The specific mechanisms by which IGFBPs affect tu-
mour progression are more complex, and discrepant 
in vitro results have been described, depending on the 
experimental conditions and type of malignancy.
Animal models: GH-IGF system excess 
Transgenic mice for human GH exhibit very high levels 
of GH in plasma and have an increased incidence of 
spontaneous mammary carcinomas. It has been dem-
onstrated, however, that activation of the prolactin 
receptor, instead of the GHR, is important for induction 
of mammary tumours in these transgenic animals [16]. 
Overexpression of human IGF-I in epidermal cells and 
prostate epithelium in transgenic mice was shown to 
induce persistent epidermal hyperplasia, spontane-
ous skin tumour formation, and spontaneous prostate 
tumorigenesis [17, 18]. The tumour-promoting effect of 
transgenic IGF-I may be independent of its binding to 
the IGFBPs [2]. This was suggested in mice overexpress-
ing the transgene des-IGF-I, an IGF-I analogue with 
low affinity for IGFBP, which retains a high binding 
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affinity for IGF-IR [19]. Accordingly, IGF-II excess in 
transgenic animals has been linked to disproportionate 
body growth, increased size of thymus, skin, kidney, 
adrenal, and testis, and development of hepatocellular, 
mammary, lung, thyroid, and colonic carcinomas, as 
well as lymphomas and sarcomas [2, 3, 20–22].
IGF-IR overexpression in transgenic mice has been 
associated with increased rate of salivary, pancreatic, 
and mammary tumour formation [23, 24]. Moreover, 
upregulation of the IGF-IR signalling axis has been 
shown to drive the survival of prostate cancer cells in 
many studies [25]. Down-regulation of IGF-IR and its 
signalling pathways have been targeted for several 
types of anti-cancer therapies, including the use of anti-
sense oligonucleotides, antisense RNA, small interfering 
RNA, triple helix-forming oligodeoxynucleotides, single 
chain antibody, fully humanised anti-IGF-IR monoclo-
nal antibodies, and specific kinase inhibitors [2]. For 
instance, A12 (a human IGF-IR antibody) was combined 
with docetaxel in one study designed to investigate 
Figure 1. The GH-IGF system. Pituitary GH secretion is stimulated by GH-releasing hormone (GHRH), and ghrelin and is inhibited by 
somatostatin (SS) and by a negative feedback effect of IGF-I. Nearly half of GH circulates in blood bound to a high-affinity GH binding 
protein (GHBP). GH receptor (GHR) activation by GH binding results in activation of JAK-STAT proteins and can also trigger other 
mitogen signaling pathways. GH stimulates IGF-I production in the liver and in several tissues. In plasma, most IGF-I circulates in 
a ternary complex with IGFBP-3 and the acid labile subunit (ALS). IGBP-3 is a GH-dependent member of a family of six IGFBPs. 
Cellular responses to the IGF-I and IGF-II are mediated by two receptors (IGF-IR and IGF-IIR), by hybrid receptors formed with the 
insulin receptor (not shown in the figure), and by IGFBP proteases. The IGF-IIR does not transduce an intracellular signal, but rather 
acts to reduce the availability of IGF-II. The mitogenic activity of the IGF-IR is mainly mediated through the Ras and AKT pathway, 
while the later also plays a critical role in cell survival by inhibiting pro-apoptotic and activating anti-apoptotic factors
Rycina 1. Oś GH-IGF. Wydzielanie GH przez przysadkę jest stymulowane przez somatoliberynę (GH-releasing hormone, GHRH) 
oraz grelinę, a hamowane przez somatostatynę (SS) oraz sprzężenie zwrotne ujemne spowodowane przez IGF-I. Niemal połowa GH 
krąży we krwi w postaci związanej z białkiem wiążącym GH (GH binding protein, GHBP). Aktywacja receptora GH (GH receptor, 
GHR) przez związanie z GH powoduje aktywację białka JAK-STAT i może również uruchamiać inne mitogenne szlaki sygnałowe. 
GH stymuluje produkcję IGF-I w wątrobie i innych tkankach. W osoczu większość IGF-I występuje w postaci trójskładnikowego 
kompleksu z IGFBP-3 i podjednostki kwasolabilnej (acid labile subunit, ALS). Białko IGBP-3 jest GH-zależne i należy do rodziny 
sześciu białek IGFBP. W odpowiedzi komórkowej na IGF-I i IGF-II pośredniczą dwa swoiste receptory (IGF-IR i IGF-IIR), hybrydowe 
receptory utworzone z receptorem insulinowym (nieprzedstawione na rycinie) oraz proteazy IGFBP. Receptor IGF-IIR nie przewodzi 
sygnałów wewnątrzkomórkowych, lecz powoduje zmniejszenie dostępności IGF-II. Aktywność mitogenna IGF-IR zależy głównie od 
aktywności szlaków Ras i AKT, przy czym ten drugi szlak ma kluczowe znaczenie dla przetrwania komórki, ponieważ hamuje czynniki 
proapoptotyczne i aktywuje czynniki o działaniu antyapoptotycznym
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the effect of blocking IGF-I signalling on human 
androgen-independent and advanced prostate tumour 
growth [26]. The results showed that the inhibition of 
IGF-IR enhanced the therapeutic effect of docetaxel on 
advanced prostate cancer. However, a recent phase II 
randomised clinical trial in chemotherapy-naïve men 
with progressing castration-resistant prostate cancer 
treated with figitumumab (a human IgG2 monoclonal 
antibody targeting IGF-IR) did not corroborate these 
preliminary findings. In this study, patients received 
figitumumab every three weeks with docetaxel/pred-
nisone (Arm A) or docetaxel/prednisone alone (Arm B1). 
At progression on Arm B1, patients could cross over 
to the combination (Arm B2). The primary endpoint, 
the prostate-specific antigen (PSA) response, did not 
improve significantly with figitumumab therapy. 
Nevertheless, a PSA response of 28% was observed in 
patients treated with the combination after disease pro-
gression with docetaxel/prednisone alone, suggesting 
that figitumumab might be more active post-docetaxel 
than in the docetaxel-naïve patients [27]. 
In contrast, overexpression of IGF-IIR and mutant 
IGF-IR molecules have been used to decrease the bio-
availability of both IGF-II and IGF-I. For instance, the 
IGFIR933 — a genetically engineered analogue derived 
from a mutated IGF1R consisting of the entire extra-
cellular domain of the IGF-IR — was expressed in 
highly metastatic H-59 murine lung carcinoma cells 
and was shown to neutralise the effects of exogenous 
IGF-I, thus diminishing IGF-I-induced signalling and 
blocking IGF-I-mediated cellular functions such as cell 
proliferation, invasion, and survival [2]. More recently, 
an IGF-targeting protein named IGF-Trap, comprising 
a soluble form of human IGF-IR and the Fc portion of 
human IgG1, was developed. The IGF-Trap has a high 
affinity for human IGF-IR and IGF-IIR, but low affinity 
for insulin receptor, and can block IGF-IR signalling in 
several carcinoma cell types and inhibit tumour cell pro-
liferation, migration, and invasion. In vivo, the IGF-Trap 
was shown to suppress growth of established breast 
carcinoma tumours, improving disease-free survival, 
and to promote markedly reduction of experimental 
liver metastasis of colon and lung carcinoma cells. The 
IGF-Trap demonstrated superior therapeutic efficacy 
in comparison with IGF-IR antibody, suggesting that 
it might overcome some limitations of current IGF-IR-
targeting agents [28].
As demonstrated in Table I, while overexpression 
or constitutive activation of GH, IGFs and IGF-IR pro-
motes carcinogenesis, experiments using gene transfer, 
upregulation, or overexpression of IGFBPs in trans-
genic animals have demonstrated marked reduction 
or attenuation of tumour growth at different tissues by 
decreasing the mitogenic activity of IGFs, and inducing 
apoptosis and/or inhibiting angiogenesis [2, 3]. In ad-
dition, the development of protease-resistant mutant 
IGFBPs, lacking the IGFBP protease cleavage sites, has 
also been investigated as potential anti-cancer therapy 
[5]. Pappalysin-1 is a metalloproteinase encoded by the 
Pappa gene, responsible for the cleavage of IGFBP4 
bound to IGF-I. In Pappa−/− mice, an abundance of 
IGFBP-4 and decreased bioavailability of IGF-I have 
been associated with a lower incidence of tumours and 
degenerative lesions, with an approximate six-month 
delay in ageing-related pathologies compared with WT 
mice [29, 30].
Table I. Tissue growth and tumour development in animal models with overexpression of individual components of the GH-
IGF system
Tabela I. Wzrost tkanek i rozwój nowotworów w modelach zwierzęcych z nadmierną ekspresją poszczególnych składowych 
osi GH-IGF
Excess Model Main findings
GH Overexpression of human GH in transgenic mice Increased incidence of mammary tumours (by activation of PRL receptor)
IGF-I Overexpression of human IGF-I in epidermal cells  
and prostate epithelium of transgenic mice
Persistent epidermal hyperplasia 
Spontaneous skin tumour formation  
Spontaneous prostate tumorigenesis
IGF-II IGF-II loss of imprinting and overexpression of IGF-II  
in mammary gland, liver, lung epithelium, skin, kidney,  
and gut of transgenic mice
Disproportionate body growth 
Increased size of thymus, skin, kidney, adrenal, and testis 
Increased incidence of lymphomas, sarcomas and carcinomas 
(hepatocellular, mammary, colonic, lung, and thyroid)
IGF-IR Overexpression of IGF-IR in mammary, pancreatic  
and salivary tissues of transgenic mice and upregulation  
of IGF-IR signalling
Increased rate of salivary, pancreatic, and mammary tumour formation 
Increased survival of prostate cancer cells
IGFBPs Gene transfer, upregulation or overexpression of IGFBPs  
in transgenic animals
Marked reduction or attenuation of tumour growth at different tissues
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Animal models: GH-IGF system deficiency 
Several mutations that decrease the tone of the GH/
IGF-1 axis are associated with protection from tumour 
development and extended longevity in animal mod-
els [31] (Table II). In Spontaneous Dwarf Rats (SDR), 
which have an inactivating mutation in the GH gene, 
investigations were conducted to assess GH action in 
the progression of mammary carcinogenesis [32–34]. 
They demonstrated that SDR rats treated with GH 
become vulnerable to mammary carcinogenesis and 
that these advanced rat mammary cancers are depend-
ent on GH for their survival. Moreover, concomitant 
steroid treatment has been shown to block GH action, 
possibly by reducing serum IGF-I levels. Resistance to 
chemical-induced tumorigenesis and impaired growth 
of tumour xenografts have also been observed in lit/lit 
mice [35–37], which are GH and IGF deficient due to a 
missense mutation resulting in loss of function of the 
pituitary GHRH receptor (GHRH-R). 
An overall reduced occurrence of neoplasms has 
been observed in GHR−/− mice throughout their lifes-
pan [38–40]. In these animals, the tumour burden (num-
ber of different types of tumours) was reduced by 47% 
compared to WT mice. As for the cause of death, 83% 
of WT mice die from neoplastic disease while only 42% 
(49% reduction) of the GHR−/− mice die from such le-
sions. The GHR−/− mouse model has also been used to 
examine the role of the GH/IGF-I axis in mammary [41] 
and prostate carcinogenesis [42]. It has been found that 
the disruption of the GH/IGF-I axis significantly retards 
TAg-driven mammary carcinogenesis in oestrogen-
independent breast cancer and confers resistance to 
prostate carcinogenesis. Additionally, a study utilising 
the GH antagonist (GHA) mouse model demonstrated 
that inhibition of the GH action could provide striking 
protection from breast cancer in vivo [43]. 
The above studies, as well as many confirming in 
vitro data, argue for the use of the GHR antagonist (peg-
visomant) for selected cancers [44]. In an early study, 
pegvisomant was examined for its impact on cancer cell 
xenografts in athymic nude mice [45]. Treatment of WT 
FVB/N mice with pegvisomant severely reduced mam-
mary development and reduced GH and IGF-I signal-
ling in mammary glands. The ability of pegvisomant to 
inhibit cancer growth was also investigated in human 
colorectal carcinoma cell lines in nude mice [46]. In this 
study, Colo205 and HT-29 cell xenographs were grown 
in nude mice until they reached a volume of 90–105 mm3 
and 60–70 mm3, respectively. The mice were then 
separated into two groups and injected every other day 
with either saline or pegvisomant at 60 mg/kg. After 
16 days of injections, pegvisomant treatment caused 
a 39% reduction in tumour volume and a 44% reduction 
in tumour weight in the nude mice with the COLO 205 
colorectal cancer. However, pegvisomant had no effect 
on the HT-29 colorectal cancer, suggesting that the inhi-
bition of GH/IGF-I may represent a treatment for some 
colorectal cancers. In a third study, a direct blockade of 
the GHR by pegvisomant was suggested to contribute 
to reduce meningioma growth and, in some instances, 
to promote tumour regression [47]. 
IGF-I knockout mice have severe developmental 
abnormalities and most do not survive, making it dif-
ficult to study how genetic ablation of IGF-I affects 
tumorigenesis. However, studies have been done in a 
mice models containing a liver-specific deletion of the 
IGF-I gene that results in a 50–75% reduction in circu-
lating IGF-1 levels associated with high GH levels. In 
agreement with other models of GH deficiency, these 
liver-specific IGF-I deficient (LID) mice exhibit a marked 
inhibition of colonic and mammary tumorigenesis and 
metastases [48, 49].
Table II. Tumour development in animal models with deficiency in components of the GH-IGF system
Tabela II. Rozwój nowotworów w modelach zwierzęcych z niedoborem składowych osi GH-IGF
Animal 
Model
Defect GH IGF-1 Tumour  
incidence
Main
Findings
SDR Inactivating mutation in the GH gene Ø Ø Ø Mammary tumours if treated with GH 
lit/lit Missense mutation in the GHRH-R gene Ø Ø Ø Resistance to chemical-induced tumorigenesis
Impaired growth of tumour xenografts
GHR–/– 
(Laron mice)
GH receptor gene disruption ≠ Ø Ø Overall reduced occurrence of neoplasms
GHA Expression of a mutated bovine GH gene exhibiting 
a classic GHR antagonism action
≠ Ø ? Protection from breast cancer development
LID Liver-specific deletion of the IGF-I gene ≠ Ø Ø Marked inhibition of mammary and colonic 
tumours and metastases
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Human studies
Epidemiological data
There is evidence of a real, albeit weak, association 
between height and cancer risk, with taller individuals 
appearing to be at increased risk for a range of cancers. 
Geographic patterns of cancer incidence and mortality 
have been associated with variations in population height, 
particularly in relation to breast, colon, and prostate can-
cer [50, 51]. A systematic review including 300 cohorts 
or nested case-control studies depicting the association 
of height and cancer found a significant increase in the 
incidence of colon, breast, and prostate cancer in taller 
individuals. Leg length was more often associated with in-
creased risk than trunk length [52]. Recent meta-analyses 
have also confirmed a positive association between height 
and ovarian, pancreatic, and kidney cancer risk [53–55]. 
It has been speculated that these findings may be partly 
mediated through IGF pathways, as genetic damage ac-
cumulation might be facilitated in taller individuals with 
IGF-I levels in the upper limits of the normal range due to 
increased rate of cell division and reduced apoptosis [56]. 
Strikingly, recent genome-wide SNP-association studies 
have identified several human height-associated genes 
that have also been linked to neoplastic growth and higher 
risk for cancer [57].
A large number of prospective epidemiological stud-
ies have found that high serum IGF-I levels (when the 
highest quartile is compared with the lowest, within the 
normal range) and/or lower levels of IGFBPs (when the 
lowest quartile is compared with the highest, within 
the normal range) are associated with increased risk for 
neoplasia at different sites, including breast, prostate, 
lung, colorectal, endometrial, thyroid, and bladder 
cancer [2, 58]. A summary of meta-analyses linking 
circulating levels of IGF-I and IGFBP-3 with the inci-
dence of the four most prevalent cancers in Western 
populations was published some years ago [3]. This 
study found that high circulating levels of IGF-I were 
positively associated with increased risk of prostate, 
breast (both in pre- and postmenopausal women) and 
colorectal cancer. Also, the lower circulating IGFBP-3 
levels were weakly associated with risks of prostate and 
breast cancer in postmenopausal women. However, the 
associations between IGFBP-3 and cancer risk disap-
peared when adjustment for IGF-1 levels took place. 
A recent investigation involving 385,747 participants from 
23 centres of 10 European countries found that IGF-I 
concentrations were positively associated with risk of 
differentiated thyroid carcinoma [58] (Fig. 2). Higher 
levels of circulating IGF-I have also been linked to an 
increased incidence of precancerous colonic adenoma 
(large or tubulovillous/villous) and cervical squamous 
intraepithelial lesions, suggesting a role for the IGF-I 
system in the early stages of transformation and car-
cinogenesis [2, 59, 60].
IGF-I gene polymorphisms, especially the allele 
containing CA19 repeats, have been associated with 
the risk for various types of cancers. A recent meta-
analysis, however, concluded that such polymorphisms 
are unlikely to be a major determinant of susceptibility 
to cancer, although in a subgroup analysis of a recessive 
model, the authors found that CA19 repeats may reduce 
the risk of certain types of cancer or may influence the 
risk in specific populations [61].
Loss of imprinting (LOI), an epigenetic alteration 
in the IGF-II gene that results in bi-allelic expression 
of IGF-II, has been reported in a variety of tumours, 
including Ewing sarcoma, rhabdomyosarcoma, Wilms’ 
tumour, clear cell sarcoma, renal cell carcinoma, ma-
lignant glioma, and a variety of gynaecological and 
testicular neoplasms [11]. Moreover, LOI of IGF-II gene 
has been identified as an individual risk factor for de-
veloping colorectal carcinoma and, more recently, with 
poor prognosis of patients with oesophageal squamous 
cell carcinoma [2, 11, 62, 63]. LOI can be assayed with 
a DNA-based blood test, and it has been proposed as 
a predictive marker of an individual’s risk for colorectal 
cancer [2, 11, 62].
Cancer on states of GH and IGF-I deficiency
Several mutations in the gene encoding for GHRH 
receptor (GHRHR) have been found in distinct popu-
lations, most of them showing a recessive mode of 
inheritance. The phenotype includes reduced, but not 
absent, serum GH, and low IGF-I levels, resulting in 
proportionate growth failure, which becomes evident in 
the first year of life [31, 64]. The largest cohort of patients 
with dwarfism caused by homozygous GHRHR muta-
tions comprises more than 100 individuals from Itaba-
ianinha, a rural area in the north-eastern Brazilian State 
of Sergipe [65]. As expected, all individuals have severe 
GH and IGF-I deficiencies, and their adult heights vary 
from 105 cm to 135 cm. The risk of death in this dwarf 
population is not different from that observed in their 
unaffected siblings, and there is no significant differ-
ence in life span between affected subjects, unaffected 
siblings, or the general population when the analysis 
is done for subjects who have reached age 20 years. 
In contrast, the life span is shorter than in the general 
population in females due to early deaths seen in those 
aged 4–20 years, mostly from diarrheal diseases. One 
death from cancer was observed in a subset of nine 
patients with dwarfism, which implies that the number 
of cancer-related deaths is unchanged compared to that 
in the general population [31, 65].
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Another important observation implicating GH 
and IGF actions in human cancer came from 2 cohorts 
of Laron individuals, who present an inactivating mu-
tation within their GHR gene, and as such, are IGF-I 
deficient due to insensitivity to GH action. In one cohort 
of 230 Laron patients, none of the individuals developed 
cancer [66]. In a second cohort located in Ecuador, out 
of a population of 99 Laron patients, only one patient 
exhibited a non-lethal malignancy, in contrast to a 17% 
cancer incidence in control individuals [67]. In this 
study, the authors were able to show that serum from 
Laron subjects reduced DNA breaks but increased ap-
optosis in human mammary epithelial cells (HMECs) 
treated with hydrogen peroxide. They also observed 
that affected individuals had increased insulin sensitiv-
ity in relation to unaffected relatives. Thus, there is an 
extraordinary and exciting reduction in the incidence 
of cancer in Laron Syndrome patients, in agreement 
with the findings in the Laron mice (GHR−/−) pointed 
out above, which exhibit a dwarf phenotype with low 
levels of IGF-1 and reduced rates of cancer [31, 38–40].
Cancer in Acromegaly
Acromegaly is a rare disease typically caused by a GH-
secreting pituitary adenoma, that represents the best 
human model to understand the consequences of a 
continuous and prolonged exposure to high GH and 
IGF-I concentrations [68]. The overall mortality rate 
is higher in patients with active acromegaly, mainly 
due to vascular and respiratory diseases, whereas 
normalisation of GH and IGF-I levels is accompanied 
by reduction of mortality rate compared to that of the 
normal population [69, 70]. Retrospective mortality 
studies have shown that, on average, 15–24% of deaths 
in acromegaly are attributable to cancer, with particular 
focus on colorectal cancer (CRC) and, to a lesser extent, 
on breast, thyroid, prostate and other cancers [71]. How-
ever, the question of whether cancer risk is increased in 
acromegaly is still under debate [72–74]. There are many 
problems and limitations in quantifying risk of cancer 
in patients harbouring a rare disease. Most studies in-
clude small numbers of individuals, with no statistical 
Figure 2. Epidemiological data linking serum IGF-I levels and cancer risk. Several prospective studies in the general population and 
meta-analyses have found an association between high serum IGF-I levels (when the highest quartile is compared with the lowest, within 
the normal range) with increased risk for prostate, breast (both in pre- and postmenopausal women), colorectal, and differentiated thyroid 
cancer. The associations between serum IGFBP-3 levels and cancer risk are weaker and usually disappear when adjustment for IGF-1 
levels is performed
Rycina 2. Dane epidemiologiczne wiążące stężenie IGF-I w surowicy z ryzykiem rozwoju nowotworu. W kilku prospektywnych 
badaniach prowadzonych w populacji ogólnej oraz metaanalizach wykazano związek między wysokim stężeniem IGF-I w surowicy 
(kiedy porównano najwyższy kwartyl z najniższym w zakresie wartości prawidłowych) ze zwiększonym ryzykiem raka prostaty, raka 
piersi (u kobiet w okresie przed- i pomenopauzalnym), raka jelita grubego i zróżnicowanego raka tarczycy. Zależności między stężeniem 
IGFBP-3 w surowicy a ryzykiem rozwoju nowotworu są słabe i zwykle znikają po skorygowaniu względem stężenia IGF-1
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power to adjust the data for confounding factors, such 
as age and gender. The comparison between older and 
more recent occurrences of the disease is challenging 
because both cancer incidence in the general popula-
tion and life expectancy in patients with acromegaly 
have dramatically changed over the past few decades, 
influencing the prevalence of disease-associated mor-
bidities. In fact, recent series have found cancer as 
a common cause of death and an independent predic-
tor of mortality in acromegaly [75–78]. In addition, 
population-based cancer registries and epidemiology 
may vary from site to site. Another source of biases 
is the heterogeneity of comparative control popula-
tions used in the studies, which have varied from data 
published in literature to hospitalised non-acromegaly 
patients, matched-controls, or the general population 
[73, 74]. Finally, the influence of acromegaly-associated 
morbidities in cancer and mortality risk is another point 
of interest. Obesity and diabetes are associated with an 
increased incidence and mortality from several types 
of malignancies in the general population [79]. There 
are several potential factors to explain the link between 
obesity, diabetes, and cancer, including insulin resist-
ance, hyperinsulinaemia, high IGF-1, hyperglycaemia, 
dyslipidaemia, and abnormalities of gut microbiome 
[79]. Remarkably, these factors might also be present in 
acromegaly and contribute to increased risk of cancer. 
In one study, an increase in fasting insulin levels was 
associated with an 8.6- to 14.8-fold increased risk of 
colonic adenomas in acromegaly [80]. In another recent 
study from three Canadian referral centres involving 
408 cases, acromegaly patients with diabetes developed 
malignant tumours almost three times as frequently as 
those without diabetes [81]. To date, most investigators 
would agree that if the risk of cancer is increased in 
acromegaly, the magnitude of this association is mod-
est, and might be clinically relevant only for colorectal 
adenocarcinomas [71, 82, 83].
GH therapy and cancer risk
Recombinant human GH (rhGH) has been used in the 
last 30 years to treat children with GH deficiency and 
short stature caused by multiple disorders, and adult 
patients with severe GH deficiency. There have been 
a substantial number of publications dedicated to long-
term surveillance for potential morbidities, including 
cancer development, in individuals being treated or 
previously exposed to rhGH. The vast experience from 
many thousands of patient-years of treatment has as-
sured a good safety profile for rhGH in children and 
adults [3, 72, 84]. Despite most favourable evidence, 
there are still reports on possible unfavourable out-
comes. Recently, the French Safety and Appropriateness 
of Growth Hormone treatments in Europe (SAGhE), 
a study carried out to evaluate the long-term mortality 
of a population-based cohort of patients treated with 
rhGH in childhood in France, found increased mor-
tality rates in adults treated as children with rhGH, 
particularly in those who received the highest doses. In 
relation to neoplasia, all type cancer-related mortality 
was not increased, but a specific effect was detected 
for bone tumours [85]. However, this was represented 
by 3 cases of bone neoplasms vs. 0.6 expected in more 
than 6500 individuals with a 95% confidence interval 
ranging from 1.01–14.61. The results of the French co-
hort have not been reproduced elsewhere. The SAGhE 
report from Sweden, Belgium, and The Netherlands, 
including a total number of person-years of observa-
tion of 46.556, identified only 21 deaths in the cohort: 
12 due to accidents, four due to suicides, and single 
cases of pneumonia, endocrine dysfunction, primary 
cardiomyopathy, deficiency of humoral immunity, and 
coagulation defect. Remarkably, there was no death 
from cancer or cardiovascular disease [86].
The constant need to address the long-term safety 
of rhGH treatment was the main motivation for the 
European Society of Paediatric Endocrinology (ESPE), 
the Growth Hormone Research Society (GRS), and the 
Paediatric Endocrine Society (PES) to convene an inter-
national meeting in 2014, which resulted in the publica-
tion of a concise position statement [87]. The document 
has addressed important issues related to rhGH therapy 
and cancer risk, as summarised in Table III. First, the 
available data in children and adults do not indicate 
an increased risk of new primary cancers in rhGH re-
cipients. It pointed out, however, some limitations for 
definitive long-term conclusions in this topic, including 
the heterogeneity of information sources, inadequate 
sample sizes to assess cancers with low incidence, lack of 
appropriate comparison populations, and small number 
of subjects with long duration of follow-up. Second, 
available data in children do not indicate an increased 
risk of recurrence of primary cancer in rhGH recipients. 
In adults, data are insufficient to fully address this 
question, but it was highlighted that available data on 
benign pituitary tumours do not indicate an increased 
risk of recurrence during long-term rhGH therapy. The 
third issue addressed was the risk of second tumours 
in GH-treated survivors of paediatric cancers. In one 
study population, the highest risk was observed early 
after rhGH treatment, declining with longer follow-up 
[88]. In contrast, a more recent report from the Child-
hood Cancer Survivor Study failed to demonstrate an 
increased occurrence of second tumours in the brain 
associated with rhGH exposure [89]. Thus, the position 
document considered this potential risk insufficient to 
preclude the use of rhGH for licensed indications in chil-
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sibility with patients and their families [87]. In patients 
surviving adult-onset malignancies, data were not 
sufficient to reach a conclusion. Regarding the appro-
priate interval between completion of cancer therapy 
and initiation of rhGH in both children and adults, the 
position recommended taking into consideration factors 
related to the tumour, time elapsed since completion 
of cancer treatment, and the importance of initiating 
rhGH treatment in an individual patient (e.g. severity 
of growth failure if patient remains untreated). Finally, 
the position document stated that definitive data are 
lacking regarding the safety of rhGH therapy in ‘high-
risk’ patients, in particular children with syndromes, 
diseases, and mutations known to be associated with 
an inherent elevated risk for cancer and early mortality 
(e.g. Neurofibromatosis type 1, Fanconi anaemia, or Down 
syndrome). In these clinical situations, the authors rec-
ommended that the decision to start therapy should be 
carefully considered and discussed with families [87].
General considerations on GH and IGF 
system as a target for cancer therapy
As previously mentioned, inhibition of GH action and 
IGF-I synthesis by pegvisomant, neutralisation of IGF 
actions, and/or blocking of IGF-IR (as well as hybrid 
receptors) and their signalling pathways are important 
targets in cancer research (Fig. 3). Many components 
of the IGF system have also been implicated in resist-
ance to anti-cancer therapies with hormonal agents, 
radiation, and chemotherapy. Therapeutic strategies 
targeting the GH and IGF system have involved dif-
ferent types of cancer with variable degrees of success. 
High-affinity antibodies are in early developmental 
stage with the aim to neutralise both IGF-I and IGF-II, 
thus inhibiting IGF signalling via IGF-IR and hybrid re-
ceptors [5, 90]. These receptors and their corresponding 
signalling pathways are currently the most important 
therapeutic targets of the IGF system. Several clinical 
trials have evaluated the efficacy of IGF-IR inhibition 
to induce anti-proliferative effects on IGF-signalling-
dependent tumours or to overcome the resistance 
mechanisms. Small molecule tyrosine kinase inhibitors 
(TKIs), anti-IGF-IR antibodies, and molecular agents, 
such as antisense and small interfering RNAs (si-RNAs), 
have been extensively investigated, but the optimal 
strategy is still not clear. The efficacy of these agents 
depends on several factors such as the expression and 
pathological importance of IGF-IR in the tumours, 
potency of inhibition, timing of use, toxicity, concomi-
tant therapies, and compensation by other signalling 
pathways [2, 4, 5]. The modest benefits reported thus 
far underscore the need for a better understanding of 
the complexity of the IGF system and its interaction 
with other pathways. It is worth mentioning that all 
trials with anti-IGF-IR antibodies alone have failed, with 
several patients developing diabetes during treatment. 
Thus, a promising alternative approach is to co-target 
IGF-IR along with other pathways known to promote 
tumorigenesis. Examples of such a strategy include 
monoclonal antibodies and TKIs targeting simultane-
Table III. Summary of the main issues addressed by position statement published on behalf of the European Society of Paediatric 
Endocrinology (ESPE), the Growth Hormone Research Society (GRS), and the Paediatric Endocrine Society (PES) related to 
recombinant human GH (rhGH) therapy and cancer risk (Allen et al, 2015)
Tabela III. Podsumowanie najważniejszych problemów uwzględnionych w publikacji przedstawiającej wspólne stanowisko 
European Society of Paediatric Endocrinology (ESPE), Growth Hormone Research Society (GRS oraz Pediatric Endocrine 
Society (PES) dotyczące wpływu leczenia rekombinowanym ludzkim czynnikiem wzrostu (recombinant human GH, rhGH) 
na ryzyko rozwoju nowotworu (Allen i wsp., 2015)
Observation Conclusions Remarks
New primary cancer Not increased in children and adults Heterogeneity of information sources 
Inadequate sample size
Lack of appropriate control populations 
Small number of subjects with long duration of follow-up
Recurrence of primary neoplasia Not increased in children 
Insufficient data in adults 
(no indication of increase)
Second tumours in survivors  
of cancer
Conflicting data in 
children-onset malignancy
Insufficient data in 
adult-onset malignancy
Potential risk insufficient to preclude the use of rhGH for licensed 
indications in children
Issue should be discussed with patients and families
‘High-risk’ groups Lack of definitive data Decision to start rhGH should be carefully considered and discussed 
with families
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ously IGF-1R and epidermal growth factor receptor 
(EGFR) [5]. In view of current knowledge, future 
strategies for cancer therapy involving the GH and IGF 
system would need to be individualised considering not 
only histologic diagnosis but the nature of the perturbed 
intracellular signalling pathways. 
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